Evolus (EOLS) Stock Price, News & Analysis

Company Overview

Evolus, Inc. is a commercial-stage medical aesthetics company focused on developing and marketing products for physicians and other licensed aesthetic providers. The company’s business is centered on minimally invasive treatments intended to address facial lines, wrinkles and other visible signs of aging.

Evolus’ primary product is Jeuveau (prabotulinumtoxinA-xvfs), an injectable botulinum toxin approved by the U.S. Food and Drug Administration for the temporary improvement of moderate to severe glabellar lines, commonly known as “frown lines,” in adults. The company markets Jeuveau as an alternative in the physician-administered aesthetic neurotoxin market and supports providers through its commercial and customer-engagement platform.

The company has expanded its international presence through product registrations and commercial activities in markets outside the United States, including Canada and certain European markets, where its botulinum toxin product is marketed under the Nuceiva brand. Evolus is headquartered in Newport Beach, California, and is led by Chief Executive Officer David Moatazedi.

Key Stats

• Today's Range: $7.24 to $7.56
• 50-Day Range: $7.01 to $9.30
• 52-Week Range: $3.86 to $9.31
• Volume: 793,582 shs
• Average Volume: 983,766 shs
• Market Capitalization: $485.47 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.50
• Consensus Rating: Moderate Buy

Evolus Stock Analysis - MarketRank™

Evolus scored higher than 49% of companies evaluated by MarketBeat, and ranked 557th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Evolus has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Evolus has a consensus price target of $14.50, representing about 97.4% upside from its current price of $7.35.

Amount of Analyst Coverage

Evolus has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Evolus are expected to grow in the coming year, from ($0.36) to $0.09 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Evolus is -13.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Evolus is -13.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.21% of the float of Evolus has been sold short.

Short Interest Ratio / Days to Cover

Evolus has a short interest ratio ("days to cover") of 7.07.

Change versus previous month

Short interest in Evolus has recently increased by 13.87%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evolus does not currently pay a dividend.

Dividend Growth

Evolus does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.43

News Sentiment

Evolus has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Evolus this week, compared to 3 articles on an average week.

Search Interest

Only 5 people have searched for EOLS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

3 people have added Evolus to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Evolus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $950,176.00 in company stock.

Percentage Held by Insiders

5.00% of the stock of Evolus is held by insiders.

Percentage Held by Institutions

90.69% of the stock of Evolus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/04/2026
• Today: 10/30/2026
• Next Earnings (Estimated): 11/04/2026
• 2026 Stifel Healthcare Conference: 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:EOLS
• CIK: 1570562
• Web: www.evolus.com
• Phone: (949) 284-4555
• Fax: N/A
• Employees: 353
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Evolus: $14.50
• High Price Target: $17.00
• Low Price Target: $13.00
• Potential Upside/Downside: +97.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.52)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$51.64 million
• Net Margins: -10.85%
• Pretax Margin: -10.64%
• Return on Equity: N/A
• Return on Assets: -13.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.70
• Quick Ratio: 1.28

Sales & Book Value

• Annual Sales: $316.49 million
• Price / Sales: 1.53
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.36) per share
• Price / Book: -20.42

Miscellaneous

• Outstanding Shares: 66,050,000
• Free Float: 62,748,000
• Market Cap: $485.47 million
• Optionable: Optionable
• Beta: 1.33